

# Cancer Bio Course 2026

## Session 3: Live group activity

Gerstner Sloan Kettering PhD programs and MSK K12 Clinical Translational Cancer Research Training Program

March 28, 2026



Memorial Sloan Kettering  
Cancer Center

**Pablo Sánchez Vela, MD**

Senior Research Scientist

Ross Levine Lab

Molecular Cancer Medicine Service

Human Oncology and Pathogenesis Program

[sanchezp@mskcc.org](mailto:sanchezp@mskcc.org)

# Rules

- I will give you a common project to develop
- In 10' turns, **you will think of experiments to do** and I will tell you the results of those and provide you some fast feedback
- Experiments are **not free** and require **time**
- **Luck** is an important factor, and so is risk-assessment
- After, you will have some time to build a story (paper) with the results you have
- One team will present their story, and the other team will criticize it
- The most complete and convincing story will WIN

# 5 Teams

## Memorial

Afroz, Jalwa  
Illouz, Sylvia  
McIlhenny, Lauren  
Pope, Eleanor  
Tarrab, Stephanie  
Minna Lee

## Sloan

Ahmed, Nibras  
Lange, Matthew  
Mutaher, Mohammed  
Prabakaran, Adithya  
Volpe, Christina  
George Li

## Kettering

Beattie, Kai  
Levin, Bailey  
Nadler, Rebecca  
Styers, Hannah  
Xiao, Michael  
Marion Liu


## Cancer

Cherkas, Shelby  
Li, Ruofei  
Pavletich, Tatiana  
Sussman, Carleigh  
Joshua Budhu  
Kanayo Nwankwo


## Center

Hanselman, Olivia  
Magnus, Karina  
Perea del Angel, Ana  
Ta, Christina  
Christina Fong  
Anupriya Singhal


# Questions I decided to tackle during my time at MSK




Genovese et al. NEJM 2014  
**Overall Mortality**




Jaiswal et al. NEJM 2014  
**Hematologic Malignancies**



Fuster et al. Science 2017  
**Cardiovascular Disease**





Coombs et al. CellStemCell 2017  
**Solid Tumors**



# Relevant relation between CH and breast cancer


- **Most common cancer in women: 287,850 in 2022 (31%)\***
- **Second most cause of cancer-related death: 43,250 in 2022 (15%)**
- **Frequent early diagnosis (60-90%):**
  - High frequency of long-term survivors.
  - Higher frequency of therapy related complications.
- **Cardiovascular/Cerebrovascular disease: Most common cause of common cause of death.**



\*Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates do not include Puerto Rico or other US territories. American Cancer Society 2022

**Local:** Surgery/Radiotherapy  
**Systemic:** Chemo/Hormono/Targeted

# First observation: Patients with Stage IV (metastatic) HER2+ Breast Cancer treated with 1st line THP (Taxol+Herceptin+Pertuzumab)



**DNMT3A CH-PD HR 1.9 (95%CI 1.04–3.46)\*\***

*\*\*MVA includes Age at blood sampling, and visceral disease.*

**First questions: How would you model this observation to establish causality?  
What is the mechanism?**






# Want a tip? Remember your hallmarks! Collaboration is key, Good luck!

Correlation + Plausibility  $\neq$  Causation

OPINION

## Common pitfalls in preclinical cancer target validation

William G. Kaelin Jr



\*Enabling characteristics

# Rules

- I will give you a common project to develop
- In 10' turns, you will think of experiments to do and I will tell you the results of those
- Experiments are not free and require time
- Luck is an important factor, and so is risk-assessment
- After, you will have some time to build a story (paper) with the results you have
- One team will present their story, and the other team will criticize it
- The most complete and convincing story will WIN

# Conclusions

- Research is **hard**, at so many levels!
- **Teamwork** capacity is crucial...Big projects in cancer research are done by big teams
- Resources are very important...but **time management** may be even more!
- Luck is an important factor you can't control, but you can control how you **react** and how you **act** after something doesn't go as expected. What are your plans: A, B, C?
- You are very **smart** guys; you are in a **great place to make science** (try to use the most unique resources it has). Get excited and have fun!

**Thanks for your attention!**

**Any questions?**



Memorial Sloan Kettering  
Cancer Center